Conference
Abstract GS6-03: Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results
Abstract
Abstract
Background: TAILORx patient-reported outcomes (PRO) quantify symptoms and health-related quality of life (HRQL) from C+E beyond E alone from the patient's perspective, thus can inform decision-making for women in the intermediate risk group for whom chemotherapy may still be considered.
Authors
Wagner L; Gray R; Garcia S; Whelan T; Tevarweerk A; Yanez B; Carlos R; Gareen I; McCaskill-Stevens W; Cella D
Volume
79
Publisher
American Association for Cancer Research (AACR)
Publication Date
February 15, 2019
DOI
10.1158/1538-7445.sabcs18-gs6-03
Conference proceedings
Cancer Research
Issue
4_Supplement
ISSN
0008-5472